Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Consolidated Net Income (2024 - 2025)

Indivior Pharmaceuticals has reported Consolidated Net Income over the past 2 years, most recently at $102.0 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at $102.0 million for Q4 2025, up 385.71% from a year ago — trailing twelve months through Dec 2025 was $210.0 million (up 2900.0% YoY), and the annual figure for FY2025 was $210.0 million, up 2900.0%.
  • Consolidated Net Income for Q4 2025 was $102.0 million at Indivior Pharmaceuticals, up from $42.0 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for INDV hit a ceiling of $102.0 million in Q4 2025 and a floor of -$98.0 million in Q2 2024.